DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1800 Fluorouracil Filtering Surgery Study Group. Five-year follow-up
of the fluorouracil filtering surgery study. Am J Ophthalmol,
1996, 121:349–366.
Fluorouracil Filtering Surgery Study Group. Fluorouracil Filtering
Surgery Study: One-year follow-up. Am J Ophthalmol, 1989,
108:625–635.
Friedman DS, Wolfs RC, O’Colmain BJ, et al. Prevalence of
open-angle glaucoma among adults in the United States. Arch
Ophthalmol, 2004, 122:532–538.
Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib
for neovascular age-related macular degeneration. N Engl J
Med, 2004, 351:2805–2816.
Grant WM, Schuman JS. Toxicology of the Eye, 4th ed.
Springfield, IL, Charles C. Thomas, 1993.
Hardten DR, Samuelson TW. Ocular toxicity of mitomycin-C.
Int Ophthalmol Clin, 1999, 39:79–90.
Hargrave SL, McCulley JP, Husseini Z. Results of a trial of combined
propamidine isethionate and neomycin therapy for
Acanthamoeba keratitis. Brolene Study Group. Ophthalmology,
1999, 106:952–957.
Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular
pressure and glaucoma progression: Results from the Early
Manifest Glaucoma Trial. Arch Ophthalmol, 2002, 120:
1268–1279.
Herpetic Eye Disease Study Group. A controlled trial of oral acyclovir
for the prevention of stromal keratitis or iritis in patients
with herpes simplex virus epithelial keratitis. The Epithelial
Keratitis Trial. Arch Ophthalmol, 1997, 115:703–712. Erratum
in: Arch Ophthalmol, 1997, 115:1196.
Herpetic Eye Disease Study Group. Acyclovir for the prevention
of recurrent herpes simplex virus eye disease. N Engl J Med,
1998, 339:300–306.
Heyman RA, Mangelsdorf DJ, Dyck JA, et al. 9-Cis retinoic acid
is a high affinity ligand for the retinoid X receptor. Cell, 1992,
68:397–406.
Hubbard GB III. Surgical management of retinopathy of prematurity.
Curr Opin Ophthalmol, 2008, 19:384–390.
Jacobson MA, Stanley H, Holtzer C, et al. Natural history and
outcome of new AIDS-related cytomegalovirus retinitis diagnosed
in the era of highly active antiretroviral therapy. Clin
Infect Dis, 2000, 30:231–233.
Jager RD, Mieler WF, Miller JW. Age-related macular degeneration.
N Engl J Med, 2008, 358:2606–2617. Erratum in:
N Engl J Med, 2008, 359:1736.
Ju WK, Kim KY, Angert M, et al. Memantine blocks mitochondrial
OPA1 and cytochrome c release and subsequent apoptotic
cell death in glaucomatous retina. Invest Ophthalmol Vis
Sci, 2008, 50:707–716.
Juzych MS, Robin AL, Novak GD. -2 Agonists in glaucoma
therapy. In: Zimmerman TJ, Kooner K, Sharir M, Fechtner
RD, eds. Textbook of Ocular Pharmacology, 3rd ed.
Philadelphia, Lippincott-Raven, 1997, pp. 247–254.
Juzych MS, Zimmerman TJ. -Blockers. In: Zimmerman TJ,
Kooner K, Sharir M, Fechtner RD, eds. Textbook of Ocular
Pharmacology, 3rd ed. Philadelphia, Lippincott-Raven, 1997,
pp. 261–275.
Kaderli B, Avci R, Yucel A, et al. Intravitreal triamcinolone
improves recovery of visual acuity in nonarteritic anterior
ischemic optic neuropathy. J Neuroophthalmol, 2007, 27:
164–168.
SECTION IX
SPECIAL SYSTEMS PHARMACOLOGY
Karkhaneh R, Naeeni M, Chams H, et al. Topical aminocaproic
acid to prevent rebleeding in cases of traumatic hyphema. Eur
J Ophthalmol, 2003, 13:57–61.
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular
Hypertension Treatment Study: A randomized trial determines
that topical ocular hypotensive medication delays or prevents
the onset of primary open-angle glaucoma. Arch Ophthalmol,
2002, 120:701–713; discussion 829–830.
Kaufman DI, Trobe JD, Eggenberger ER, Whitaker JN. Practice
parameter: The role of corticosteroids in the management of
acute monosymptomatic optic neuritis. Report of the Quality
Standards Subcommittee of the American Academy of
Neurology. Neurology, 2000, 54:2039–2044.
Kaufman PL, Gabelt BAT. Direct, indirect, and dual-action
parasympathetic drugs. In: Zimmerman TJ, Kooner K, Sharir
M, Fechtner RD, eds. Textbook of Ocular Pharmacology,
3rd ed. Philadelphia, Lippincott-Raven, 1997, pp. 221–238.
Kaur IP, Kanwar M. Ocular preparations: The formulation
approach. Drug Dev Ind Pharm, 2002, 28:473–493.
Kunou N, Ogura Y, Yasukawa T, et al. Long-term sustained
release of ganciclovir from biodegradable scleral implant for
the treatment of cytomegalovirus retinitis. J Control Release,
2000, 68:263–271.
Laties AM. Vision disorders and phosphodiesterase type 5
inhibitors: A review of the evidence to date. Drug Saf, 2009,
32:1–18.
Lee VHL. Precorneal, corneal, and postcorneal factors. In: Mitra
AK, ed. Ophthalmic Drug Delivery Systems. New York,
Marcel Dekker, 1993, pp. 59–82.
Levin AA, Sturzenbecker LJ, Kazmer S, et al. 9-Cis retinoic acid
stereoisomer binds and activates the nuclear receptor RXR .
Nature, 1992, 355:359–361.
Levkovitch-Verbin H, Martin KR, Quigley HA, et al.
Measurement of amino acid levels in the vitreous humor of
rats after chronic intraocular pressure elevation or optic nerve
transection. J Glaucoma, 2002, 11:396–405.
Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes
in the Collaborative Initial Glaucoma Treatment Study
comparing initial treatment randomized to medications or surgery.
Ophthalmology, 2001, 108:1943–1953.
Lien S, Lowman HB. Therapeutic anti-VEGF antibodies. Handb
Exp Pharmacol, 2008, 181:131–150.
Liesegang TJ. Varicella-zoster virus eye disease. Cornea, 1999,
18:511–531.
Lindsey JD, Gaton DD, Sagara T, et al. Reduced TIGR/myocilin
protein in the monkey ciliary muscle after topical prostaglandin
F (2) treatment. Invest Ophthalmol Vis Sci, 2001, 42:1781–1786.
Lloyd MJ, Fraunfelder FW. Drug-induced optic neuropathies.
Drugs Today (Barc), 2007, 43:827–836.
Love JM, Gudas LJ. Vitamin A, differentiation and cancer. Curr
Opin Cell Biol, 1994, 6:825–831.
Mangelsdorf DJ, Umesomo K, Evans RM. The retinoid receptors.
In: Sporn MB, Roberts AB, Goodman DS, eds. The
Retinoids: Biology, Chemistry, and Medicine, 2nd ed. New
York, Raven Press, 1994, pp. 319–349.
Marx JL, Kapusta MA, Patel SS, et al. Use of the ganciclovir
implant in the treatment of recurrent cytomegalovirus retinitis.
Arch Ophthalmol, 1996, 114:815–820.
McCulley JP, Alizadeh H, Niederkorn JY. The diagnosis and management
of Acanthamoeba keratitis. CLAO J, 2000, 26:47–51.